FDA warning letter
Issue date
21 Feb 2019
Issuing office
Division of Pharmaceutical Quality Operations I
Posted date
2 Apr 2019
Subject
CGMP/Finished Pharmaceuticals/Adulterated
Products & Services
Drugs
Inopak
Warning letter
Headquarters
United States of AmericaSites
United States of America